Donepezil overdose: A tenfold dosing error

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 812-815

  Shepherd, Greene ^a,b,d   Klein Schwartz, Wendy ^e   Edwards, Robin ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^c UNION MEMORIAL HOSPITAL   (United States)

^d North Texas Poison Center   (United States)

^e NONE

Author keywords

Donepezil; Dosing; Toxicity

Indexed keywords

ATROPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; BRADYCARDIA; CASE REPORT; DRUG OVERDOSE; FEMALE; HUMAN; HYPERTENSION; LUNG EDEMA; NAUSEA; NURSING HOME; PRIORITY JOURNAL; VOMITING;

EID: 0032802044     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18273     Document Type: Article

References (20)

1. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67-75.
2. Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger AJ. The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem 1996;4:1429-46.
3. Package insert. Aricept (donepezil). Teaneck, NJ: Eisai America and New York: Pfizer, Inc., June 1996.
4. Bird TD. Alzheimer's disease and other primary dementias. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:2348-56.
5. Shintani EY, Ushida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm 1997;54:2805-10.
6. Ohnishi A, Mihari M, Kamura H, Tomono Y, Hasegawa J, Yamazaki K, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993;33:1086-91.
7. Aaron CK, Howland MA. Insecticides: organophosphates and carbamates. In: Goldfrank LR, Flomenbaum NE, Lewin NA, Weisman RA, Howland MA, Hoffman RS, eds. Goldfrank's toxicologic emergencies. 6th ed. New York: Appleton & Lange, 1998:1429-49.
8. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
9. Greene YM, Novisasky J, Tariot PN. Donepezil overdose (letter). J Clin Psychiatry 1999;60:56-7.
10. Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird CE, Molinoff PB, Ruddon RW, eds. Goodman and Gilman's the pharmacologic basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:161-76.
11. Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980;9:588-90.
12. Walker WE, Levy RC, Hanenson IB. Physostigmine - its use and abuse. J Am Coll Emerg Physicians 1976;5:436-9.
13. Cummings G, Harding LK, Prowse K. Treatment and recovery after massive overdose of physostigmine. Lancet 1968;5824:147-9.
14. Klein-Schwartz W, Oderda GM, Booze L. Poisoning in the elderly. J Am Geriatr Soc 1983;31:195-9.
15. Gish FL. Issues excerpted from medication error analysis - June 30, 1993 through June 1, 1994. Rockville, MD: The United States Pharmacopeial Convention, 1994.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
17. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four year study. J Am Geriatr Soc 1996;44:194-7.
18. McGoodwin L. Poison prevention in the elderly. J Okla State Med Assoc 1996;89:173-6.
19. Pepper GA. Errors in drug administration by nurses. Am J Health Syst Pharm 1995;52:390-5.
20. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm 1993;50:305-14.